AXDX Accelerate Diagnostics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AXDX

Price (delayed)

$4.32

Market cap

$62.86M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.01

Enterprise value

$79.27M

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC ...

Highlights
AXDX's debt has shrunk by 52% YoY
Accelerate Diagnostics's EPS has increased by 38% YoY and by 24% from the previous quarter
The revenue has declined by 9% year-on-year but it has grown by 2.9% since the previous quarter
The quick ratio fell by 28% YoY
The gross margin fell by 17% QoQ
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://acceleratediagnostics.com/
Peers: TMO BDX BIO NSTG

Key stats

What are the main financial stats of AXDX
Market
Shares outstanding
14.55M
Market cap
$62.86M
Enterprise value
$79.27M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
5.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.6
Earnings
Revenue
$12M
EBIT
-$55.96M
EBITDA
-$52.73M
Free cash flow
-$43.02M
Per share
EPS
-$6.01
Free cash flow per share
-$2.98
Book value per share
-$2.44
Revenue per share
$0.83
TBVPS
$2.72
Balance sheet
Total assets
$39.32M
Total liabilities
$74.36M
Debt
$36.57M
Equity
-$35.03M
Working capital
-$5.34M
Liquidity
Debt to equity
-1.04
Current ratio
0.86
Quick ratio
0.63
Net debt/EBITDA
-0.31
Margins
EBITDA margin
-439.3%
Gross margin
23%
Net margin
-526.7%
Operating margin
-477%
Efficiency
Return on assets
-123.2%
Return on equity
N/A
Return on invested capital
-238.2%
Return on capital employed
-3,638.6%
Return on sales
-466.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AXDX stock price

How has the Accelerate Diagnostics stock price performed over time
Intraday
2.86%
1 week
-6.9%
1 month
-27.09%
1 year
-95.02%
YTD
-93.88%
QTD
-24.87%

Financial performance

How have Accelerate Diagnostics's revenue and profit performed over time
Revenue
$12M
Gross profit
$2.76M
Operating income
-$57.26M
Net income
-$63.23M
Gross margin
23%
Net margin
-526.7%
AXDX's net margin is up by 23% QoQ and by 2.2% YoY
The company's net income rose by 21% QoQ and by 11% YoY
The gross margin fell by 17% QoQ
The operating income has increased by 16% year-on-year

Growth

What is Accelerate Diagnostics's growth rate over time

Valuation

What is Accelerate Diagnostics stock price valuation
P/E
N/A
P/B
N/A
P/S
5.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.6
Accelerate Diagnostics's EPS has increased by 38% YoY and by 24% from the previous quarter
AXDX's equity is up by 9% QoQ
AXDX's price to sales (P/S) is 91% less than its 5-year quarterly average of 55.5 and 15% less than its last 4 quarters average of 6.1
The revenue has declined by 9% year-on-year but it has grown by 2.9% since the previous quarter

Efficiency

How efficient is Accelerate Diagnostics business performance
Accelerate Diagnostics's ROS has increased by 27% from the previous quarter and by 6% YoY
Accelerate Diagnostics's ROA has decreased by 25% YoY but it has increased by 7% from the previous quarter

Dividends

What is AXDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AXDX.

Financial health

How did Accelerate Diagnostics financials performed over time
The company's total assets is 47% lower than its total liabilities
The company's total assets fell by 48% YoY and by 21% QoQ
The quick ratio fell by 28% YoY
Accelerate Diagnostics's debt to equity has soared by 86% YoY but it has decreased by 9% from the previous quarter
AXDX's debt has shrunk by 52% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.